Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock By Investing.com
    News

    Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock By Investing.com

    userBy userJanuary 17, 2025No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Bennett C. Frank, Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals Inc. (NASDAQ:), recently reported a significant stock transaction. According to the latest SEC filing, Frank sold 6,752 shares of Ionis common stock on January 16, 2025. The shares were sold at an average price of $32.896, amounting to a total transaction value of $222,113. The transaction comes as Ionis shares trade near their 52-week low of $31.40, with the stock down approximately 38% over the past year. The company, currently valued at nearly $5 billion, has faced challenging market conditions.

    In addition to the sale, the filing also disclosed that Frank acquired 18,011 shares of common stock on January 15, 2025, through the vesting of Restricted Stock Units. These shares were acquired at no cost, as part of his compensation package. According to InvestingPro, which offers comprehensive analysis and 8 additional key insights about Ionis, the company currently operates with moderate debt levels while maintaining strong liquidity.

    Following these transactions, Frank holds a total of 90,866 shares of Ionis Pharmaceuticals. The stock transactions were carried out as part of routine financial management and compliance with the company’s equity incentive plans.

    In other recent news, Ionis Pharmaceuticals has seen significant developments with the FDA’s approval of its drug, TRYNGOLZA, for the treatment of Familial Chylomicronemia Syndrome (FCS). Piper Sandler maintained its Overweight rating for Ionis, aligning with the company’s positive outlook. The drug, priced at $595,000 per year, is expected to generate $37 million in U.S. FCS revenue for the fiscal year 2025, according to Piper Sandler’s projections.

    On the other hand, Needham maintained its Buy rating for Ionis, with a price target of $60.00. The approval of TRYNGOLZA is a significant milestone for the company and is expected to reduce triglycerides by 30.0% at the six-month mark. Needham projects TRYNGOLZA’s revenue in 2025 to be $27 million, slightly under the current consensus estimate of $28 million.

    Furthermore, Ionis reported its third-quarter financial results for 2024, emphasizing the importance of non-GAAP financial results. The company believes these figures more accurately reflect its business operations and long-term prospects. These recent developments highlight Ionis Pharmaceuticals’ progress and potential in the pharmaceutical industry.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleUS says Ronald Greene’s death showed Louisiana police used excessive force By Reuters
    Next Article Here are 11 things Trump has promised to carry out on Day 1 of his presidency
    user
    • Website

    Related Posts

    Is ‘SIMAGA’ the secret to avoiding stock market crashes?

    July 10, 2025

    Is this FTSE 250 stock gearing up to more than double its market cap by October?

    July 10, 2025

    My 3 ‘secret’ rules I always follow when hunting passive income stocks

    July 10, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d